Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.
- DOI
- 10.1111/1759-7714.70299
- Published
- 2026 May
- Container
- Thoracic cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/1759-7714.70299,
title = {Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.},
author = {Yamamoto N and Kenmotsu H and Ninomiya K and Akdemir B and Uematsu S and Fukui A and Koto R and Fujiwara M and Iwao C and Kitagawa H and Yoshino I and Gemma A and Mitsudomi T and Saito Y},
year = {2026},
journal = {Thoracic cancer},
doi = {10.1111/1759-7714.70299},
url = {https://doi.org/10.1111/1759-7714.70299}
}RIS
TY - JOUR TI - Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study. AU - Yamamoto N AU - Kenmotsu H AU - Ninomiya K AU - Akdemir B AU - Uematsu S AU - Fukui A AU - Koto R AU - Fujiwara M AU - Iwao C AU - Kitagawa H AU - Yoshino I AU - Gemma A AU - Mitsudomi T AU - Saito Y PY - 2026 JO - Thoracic cancer DO - 10.1111/1759-7714.70299 UR - https://doi.org/10.1111/1759-7714.70299 ER -
APA
N, Y., H, K., K, N., B, A., S, U., A, F., R, K., M, F., C, I., H, K., I, Y., A, G., T, M., & Y, S. (2026). Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study.. Thoracic cancer. https://doi.org/10.1111/1759-7714.70299
Source records
- pubmed · retrieved 2026-09-26T02:02:34.902Z